Designing Of Slns Encapsulating Busulfex Association In Gene Polymorphism And Its Treatment Outcome For Head And Neck Cancer
Keywords:
Busulfan, Solid Lipid Nanoparticles, drug encapsulation, cancer treatmentAbstract
This research is dedicated to the creation and analysis of Chitosan Nanoparticles loaded with Busulfan for potential medical applications. The main goal was to produce nanoparticles with specific physical and chemical properties and a sustained release of the drug. Nine different formulations (CNB-1 to CNB-9) were developed using varying concentrations of chitosan and tripolyphosphate (TPP) via a method called ionic gelation. The nanoparticles underwent extensive testing for their size distribution, electrical charge, drug entrapment efficiency, drug content, and how the drug was released over time in vitro. The results showed that CNB-4 had the most desirable characteristics, with an average size of 172 ± 2 nanometers, a slight positive charge (4 ± 1 millivolts), high drug entrapment, and a slow release of the drug over 24 hours. Further examination using techniques like Differential Scanning Calorimetry (DSC) and Atomic Force Microscopy (AFM) confirmed that CNB-4 was successfully formed and had a solid structure. DSC analysis showed no interactions between the drug and the polymer, while AFM images displayed dense, spherical nanoparticles. Over the course of 24 hours, CNB-4 released almost 90% of the therapeutic payload, according to in vitro release assays, demonstrating a continuous release of the medication. Statistical analysis revealed a strong correlation between the physical and chemical properties of the formulations and their release rates. In conclusion, CNB-4's favourable features made it an attractive prospect for controlled drug delivery in treatment for cancer. The findings of this study can be used to enhance drug delivery systems that rely on nanoparticles and to better understand how to optimise formulation parameters to achieve desired therapeutic effects.
References
Certainly, here are all 29 references formatted in IEEE style:
V. Mishra, K. Bansal, A. Verma, N. Yadav, S. Thakur, K. Sudhakar and J. Rosenholm, "Solid lipid nanoparticles: emerging colloidal nano drug delivery systems," Pharmaceutics, vol. 10, no. 4, p. 191, 2018.
E. B. Souto and R. H. Muller, "Lipid nanoparticles (solid lipid nanoparticles and nanostructured lipid carriers) for cosmetic, dermal, and transdermal applications," Drugs Pharmaceut. Sci., vol. 166, p. 213, 2007.
S. A. Wissing, O. Kayser and R. H. Müller, "Solid lipid nanoparticles for parenteral drug delivery," Adv. Drug Deliv. Rev., vol. 56, no. 9, pp. 1257-1272, 2004.
J. Pardeike, A. Hommoss and R. H. Müller, "Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products," Int. J. Pharm., vol. 366, no. 1, pp. 170-184, 2009.
T. Eldem, P. Speise and A. Hincal, "Optimization of spray-dried and congealed lipid microparticles and characterization of their surface morphology by scanning electron microscopy," Pharmaveutical Research, vol. 8, no. 3, pp. 47-54, 1991.
L. Xu, X. Wang, Y. Liu, G. Yang, R. J. Falconer and C. X. Zhao, "Lipid nanoparticles for drug delivery," Adv. NanoBiomed Res., vol. 2021, article 2100109.
J. Weiss, E. A. Decker, D. J. McClements, K. Kristbergsson, T. Helgason and T. Awad, "Solid lipid nanoparticles as delivery systems for bioactive food components," Food Biophys., vol. 3, no. 2, pp. 146-154, 2008.
R. Cavalli, M. R. Gasco, P. Chetoni, S. Burgalassi and M. F. Saettone, "Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin," Int. J. Pharm., vol. 238, no. 1, pp. 241-245, 2002.
L. A. S. Bahari and H. Hamishehkar, "The impact of variables on particle size of solid lipid nanoparticles and nanostructured lipid carriers; a comparative literature review," Adv. Pharmaceut. Bull., vol. 6, no. 2, 2016.
J. Ezzati Nazhad Dolatabadi, H. Hamishehkar and H. Valizadeh, "Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: solid-state characterization and aerosol dispersion performance," Drug Dev. Ind. Pharm., vol. 41, no. 9, pp. 1431-1437, 2015.
S. G. Padhye and M. S. Nagarsenker, "Simvastatin solid lipid nanoparticles for oral delivery: formulation development and In vivo evaluation," Indian J. Pharmaceut. Sci., vol. 75, no. 5, p. 591, 2013.
V. Kakkar, S. Singh, D. Singla and I. P. Kaur, "Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin," Mol. Nutr. Food Res., vol. 55, no. 3, pp. 495-503, 2011.
W. Mehnert and K. Mäder, "Solid lipid nanoparticles: production, characterization and applications," Adv. Drug Deliv. Rev., vol. 47, no. 2, pp. 165-196, 2001.
P. Ghasemiyeh and S. Mohammadi-Samani, "Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages," Res. Pharmaceut. Sci., vol. 13, no. 4, p. 288, 2018.
S. Mukherjee, S. Ray and R. S. Thakur, "Solid lipid nanoparticles: modern formulation in drug delivery system," Indian journal of Pharmaceutical sciences, vol. 71, no. 4, pp. 349-358, 2009.
D. Butani, C. Yewale and A. Misra, "Topical Amphotericin B solid lipid nanoparticles: design and development," Colloids Surf. B Biointerfaces, vol. 139, pp. 17-24, 2016.
R. H. Muller, K. Mader and S. Gohla, "Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art," Eur. J. Pharm. Biopharm., vol. 50, no. 1, pp. 161-177, 2000.
S. V. Khairnar, P. Pagare, A. Thakre, A. R. Nambiar, V. Junnuthula, M. C. Abraham, P. Kolimi, D. Nyavanandi and S. Dyawanapelly, "Review on the scale-up methods for the preparation of solid lipid nanoparticles," Pharmaceutics, vol. 6;14, no. 9, p. 1886, 2022.
A. J. Almeida and E. Souto, "Solid lipid nanoparticles as a drug delivery system for peptides and proteins," Adv. Drug Deliv. Rev., vol. 59, no. 6, pp. 478-490, 2007.
K. Rajpoot, "Solid lipid nanoparticles: a promising nanomaterial in drug delivery," Curr. Pharmaceut. Des., vol. 25, no. 37, pp. 3943-3959, 2019.
S. P. Chaturvedi and A. Mishra, "Production technique of lipid nanoparticles," Res. J. Pharmaceut. Biol. Chem. Sci., vol. 3, no. 3, pp. 525-541, 2012.
P. Ekambaram, A. A. H. Sathali and K. Priyanka, "Solid lipid nanoparticles: a review," Scientific reviews and chemical communications, vol. 2, no. 1, pp. 80-102, 2011.
P. Chakravarty, A. Famili, K. Nagapudi and M. A. Al-Sayah, "Using supercritical fluid technology as a green alternative during the preparation of drug delivery systems," Pharmaceutics, vol. 11, no. 12, p. 629, Nov. 25, 2019.
M. Trotta, F. Debernardi and O. Caputo, "Preparation of solid lipid nanoparticles by a solvent emulsification–diffusion technique," Int. J. Pharm., vol. 257, no. 1, pp. 153-160, 2003.
G. Anderluzzi, G. Lou, Y. Su and Y. Perrie, "Scalable manufacturing processes for solid lipid nanoparticles," Pharm. Nanotechnol., vol. 7, no. 6, pp. 444-459, 2019.
A. Vogelaar, S. Marcotte, J. Cheng, B. Oluoch and J. Zaro, "Use of microfluidics to prepare lipid-based nanocarriers," Pharmaceutics, vol. 15, no. 4, Mar. 24, 2023, p. 1053.
F. Sommonte, I. Arduino, R. M. Iacobazzi, M. Tiboni, F. Catalano, R. Marotta, M. Di Francesco, L. Casettari, P. Decuzzi, A. A. Lopedota and N. Denora, "Microfluidic assembly of 'Turtle-Like' shaped solid lipid nanoparticles for lysozyme delivery," Int. J. Pharm., vol. 5, no. 631, 2023, Article 122479.
S. Dattani, X. Li, C. Lampa, D. Lechuga-Ballesteros, A. Barriscale, B. Damadzadeh and B. R. Jasti, "A comparative study on micelles, liposomes and solid lipid nanoparticles for paclitaxel delivery," Int. J. Pharm., vol. 631, Jan. 25, 2023, Article 122464.
I. Arduino, Z. Liu, A. Rahikkala, P. Figueiredo, A. Correia, A. Cutrignelli, N. Denora and H. A. Santos, "Preparation of cetyl palmitate-based PEGylated solid lipid nanoparticles by microfluidic technique," Acta Biomater., vol. 121, pp. 566-578, 2021.